Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 6/20 | 0.54 |
| ▸ | DRD2 | P14416 | 5/20 | 0.54 |
| ▸ | DRD3 | P35462 | 2/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.49 |
| ▸ | UBE2M | P61081 | 2/20 | 0.49 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | SCN4A | P35499 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12280116 | 1.00 | DRD4 (0.54) | DRD4DRD2DRD3MCHR1UBE2M | |
| SCHEMBL27890304 | 0.87 | DRD4 (0.50) | DRD4DRD2DRD3MCHR1UBE2M | |
| SCHEMBL14831782 | 0.83 | UBE2M (0.53) | DRD4DRD2DRD3MCHR1UBE2M | |
| SCHEMBL4390012 | 0.83 | DRD4 (0.65) | DRD4DRD2MCHR1SIGMAR1ACHE | |
| SCHEMBL6865672 | 0.83 | DRD4 (0.65) | DRD4DRD2MCHR1SIGMAR1ACHE | |
| SCHEMBL4369301 | 0.82 | DRD2 (0.56) | DRD4DRD2DRD3MCHR1SIGMAR1 | |
| SCHEMBL4369305 | 0.82 | DRD2 (0.56) | DRD4DRD2DRD3MCHR1SIGMAR1 | |
| SCHEMBL4372414 | 0.82 | DRD2 (0.56) | DRD4DRD2DRD3MCHR1SIGMAR1 | |
| SCHEMBL4372426 | 0.82 | DRD2 (0.56) | DRD4DRD2DRD3MCHR1SIGMAR1 | |
| SCHEMBL4369297 | 0.82 | DRD2 (0.56) | DRD4DRD2DRD3MCHR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2361902-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | JAK3, JAK2, JAK1 | DRD4 819/4885DRD2 1167/4885DRD3 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.